• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

No difference between placebo, amitriptyline and topiramate in reducing pediatric migraine: The CHAMP trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
January 12, 2017
in Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this study, no significant intergroup differences between amitriptyline, topiramate and placebo for reduction in total number of headache days was observed.

2. Amitriptyline and topiramate were associated with significantly higher rates of adverse side effects compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Pediatric migraine poses a substantial economic burden and reduction in quality of life for those affected. Yet practice guidelines for management of pediatric migraine are consensus based, rather than evidence based. In the Childhood and Adolescent Migraine Prevention (CHAMP) trial, researchers assessed the effects of a 24-week course of amitriptyline compared to topiramate or placebo in pediatric and adolescent migraine patients’ ages 8-17 years with regards to reduction in the overall number of headache days compared to pre-trial baseline. Neither amitriptyline nor topiramate was found to be more effective than placebo with regards to reducing overall headache days compared to pre-trial baseline. Additionally, there were no inter-group differences in secondary outcomes, including headache-related disability, total headache days. The trial was subsequently concluded early for futility after interim analysis. Patients in the amitriptyline and topiramate group did experience significantly higher rates of adverse effects compared to placebo.

Click to read the study, published today in NEJM

Relevant Reading: Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses.

In-Depth [randomized controlled trial]: In this randomized, double-blind, placebo-controlled study, 328 participants were included in the primary analysis, with 132, 130 and 66 participants randomized to receive amitriptyline, topiramate and placebo, respectively. The primary outcome was the relative reduction of ≥50% in the number of headache days relative to a 28-day pre-trial baseline. The primary analysis occurred in 52%, 55% and 61% of participants in the amitriptyline, topiramate and placebo groups respectively. With regards to intergroup comparisons, the adjusted odds ratio for amitriptyline compared to placebo was 0.71 (98%CI 0.31-1.48; p = 0.26) and for topiramate vs. placebo, it was 0.81 (98.3%CI 0.39-1.68; p = 0.48). There were no significant between-group differences in headache-related disability. Adverse effects in the amitriptyline and topiramate group were significantly higher compared to placebo. Notably, the amitriptyline group, when compared to the placebo group, had significantly higher rates of fatigue (30% vs.14%; p = 0.01) and dry mouth (25% vs. 12%; p = 0.03). The topiramate compared to placebo group had significantly higher rates of paresthesia (31% vs. 8%; p < 0.001) and weight loss (8% vs 0%; p = 0.02).

RELATED REPORTS

2 Minute Medicine Rewind June 6, 2022

Ambient air pollution associated with increased risk of Kawasaki disease in children

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: migrainepediatrics
Previous Post

Radiolabeled somatostatin analogue linked with improved survival in neuroendocrine tumors

Next Post

Antibody-based imaging can monitor prostate cancer progression [PreClinical]

RelatedReports

Weekly Rewinds

2 Minute Medicine Rewind June 6, 2022

June 6, 2022
Isolated mild/moderate thrombocytopenia may not require intervention
Pediatrics

Ambient air pollution associated with increased risk of Kawasaki disease in children

May 9, 2022
#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
Late gestation antidepressant use linked to postpartum hemorrhage
Weekly Rewinds

2 Minute Medicine Rewind April 13, 2022

April 18, 2022
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Antibody-based imaging can monitor prostate cancer progression [PreClinical]

Combined MRI and NIH stroke scores may predict stroke prognosis

2 Minute Medicine Rewind January 16, 2017

UTI associated with increased risk of preeclampsia

Review suggests use of standard rather than intensive blood pressure treatment in the elderly

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.